Download pdf - NILSSON

Transcript
Page 1: NILSSON

EarlyEarly VascularVascular AgeingAgeing (EVA) (EVA) syndromesyndrome–– couldcould it be it be defineddefined??

Peter M Nilsson, MD, PhDDepartment of Clinical Sciences

University Hospital, MalmöSweden

Summer School, Athens, 3rd July 2010Hellenic Atherosclerosis Society

Page 2: NILSSON

Age and cardiovascular disease• Age - a greater risk factor than traditional risk factors• Age-related changes in vascular structure and function,

in association with metabolic disturbances, are likely to be responsible for increased cardiovascular risk

Najjar et al. Hypertension 2005; 46:454-462.

Increase in CAD, Hypertension, CHF,

stroke

Increased exposure to risk factors

Changes in the vessel wall

Increasing Age

Page 3: NILSSON

IntermediateLesion

Minamino T, Circ Res 2007;100;15-26

Early Vascular Ageing (EVA): Early Vascular Ageing (EVA): Atherosclerosis and arterial stiffeningAtherosclerosis and arterial stiffening

FoamCells

FattyStreak Atheroma

FibrousPlaque

ComplicatedLesion/Rupture

Endothelial Dysfunction

From First Decade From Third Decade From Fourth Decade

Growth of the Lipid CoreSmooth

Muscle and Collagen

Thrombosis

Nilsson PM, et al. J Hypertens 2008, Hypertension 2009

Page 4: NILSSON

Core characteristics of EVA

• Arteriosclerosis• Arterial stiffness: PWV ↑ , Aix ↑, central BP ↑

• Endothelial dysfunction• NO deficiency, dysfunction, local inflammation

• Atherosclerosis• Imaging (IMT, plaque), biomarkers

Nilsson PM, et al. Hypertension 2009

Page 5: NILSSON

Laurent, S. et al. Eur Heart J 2006 27:2588-2605.

Measurement of carotid-femoral PWV with the foot to foot method

Page 6: NILSSON

EVA definitions – Three options

• No definition needed– EVA is only a model for (dynamic) thinking about

CV risk, beyond Framingham, SCORE and the Metabolic syndrome

Page 7: NILSSON

EVA definitions – Three options

• No definition needed– EVA is only a model for (dynamic) thinking about

CV risk

• Outside normal range of PWV– Define outliers (+ 2SD) of PWV distribution

The Reference Values for Arterial Stiffness' Collaboration.Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 Jun 7. [Epub ahead of print]

Page 8: NILSSON

Normal values for pulse wave velocityaverage according to age (1455 healthy NT subjects)

Eur Heart J 2010;eurheartj.ehq165Laurent S, et al, for a Collaborative Group

NT = normotensives (out of a total 16,867 subjects from 8 European countries)

Page 9: NILSSON

Pulse wave velocity (PWV) vs. age and MBP

Eur Heart J 2010;eurheartj.ehq165

Page 10: NILSSON

Reference values for pulse wave velocity (PWV): mean values according to age and blood pressure (BP) categories (11 092 subjects)

Eur Heart J 2010;eurheartj.ehq165

Page 11: NILSSON

PWV distribution and age in Malmö

• Population-based screening study in elderly subjects; mean 70 years (Malmo Diet Cancer Re-exam Study)

• Sphygmocor for PWV measurement in 2380 subjects

• Elevated PWV ( �12 m/s) för men (M) and women (W) in different age-ranges (quartiles of age distribution):

– 62-67 years: 10.2% (M: 15.1, W: 6.7)– 68-72 years: 17.2% (M: 20.5, W: 14.9)– 73-77 years: 31.7% (M: 38.3, W: 27.8)– 78-84 years: 41.2% (M: 42.4, W: 40.1)

Nilsson P, Östling G, 2010

Page 12: NILSSON

PWV and risk prediction• Two new studies based on meta-analysis

• 17 studies, 15,877 subjects. Pooled RRs for high-risk category were:– CV events RR 2.26 (95%CI: 1.89-2.70)– CV mortality RR 2.02 (95%CI: 1.68-2.42)– All-cause mortality RR 1.90 (95%CI: 1.61-2.24)

• Vlachopoulos C, et al. J Am Coll Cardiol 2010; 55:1318-27

• 12 studies, 15,220 subjects, 1779 combined events, analysis based on individual data– CV events HR 1.27 for 1 SD– CHD HR 1.19 for 1 SD– Stroke HR 1.25 for 1 SD

• McEniery C, et al. Abstract, ESH XX Meeting, Oslo 17-21 June 2010

Page 13: NILSSON

EVA definitions – Three options

• No definition needed– EVA is only a model for (dynamic) thinking about CV risk

• Outside normal range of PWV– Define outliers (+ 2SD) of PWV distribution

• The unexplained component of PWV– What remains after full adjustment for conventional risk

factors (age, gender, blood pressure, lipids, smoking, glucose, etc.) in multiple regression analysis

Page 14: NILSSON

Put EVA to the test!

• Genetics of arterial stiffness and EVA– Do genetic markers also predict CV events?

• Reversibility of arterial stiffness– Possible with or without BP reduction?

• New drugs for vascular protection– AT2 agonists, endothelial modulators,

incretins (GIP, GLP-1), etc.

Page 15: NILSSON

DPP-4=dipeptidyl peptidase-4; T2DM=type 2 diabetes mellitusAdapted from Unger RH. Metabolism. 1974; 23: 581–593. Ahrén B. Curr Enzyme Inhib. 2005; 1: 65–73.

↑ Insulin

↓ Glucagon

Improved glycemic control

Incretin activity

prolonged

Improved islet function

DPP-4 inhibitor

↓ Insulin

↑ Glucagon

HyperglycemiaIncretin

response diminished

Further impaired islet function

T2DM

Blocking DPP-4 Can Improve Incretin Activity and Correct the Insulin:Glucagon Ratio in T2DM

Page 16: NILSSON

New studies with incretins for evaluation of CV prevention

• Randomised controlled trials

• TECOS – sitagliptin (2009)• SAVOR – saxagliptin (2010)• CAROLINA – linagliptin (2010)• LEADER - liraglutide (2010)

• Observational study

• EDGE - vildagliptin (2009)

PN 2010

Page 17: NILSSON

Future directions – EVA in translation

• Understanding

• Translational Research

• Prevention

Page 18: NILSSON

Future directions (1)

• Understanding

– Epidemiological studies in different populations

– Molecular biogerontology(www.whyweage.eu)

– Glucose metabolism and EVA (www.diamap.eu)

Page 19: NILSSON

- A research network across Europe, aiming for writing backgrounddocuments for future EU Research calls and funding.

- Final meeting held in Brussels on 17-19th May 2010.

- Increasing interest shown in telomere biology, e.g. in relationto cellular senescence and vascular ageing.

www.whyweage.eu HEALTH-F4-2008-200970 Dec 1st 2008 - May 30th 2010

Page 20: NILSSON

Increased Thickness and Cellularity of the Human Intima with Aging

Courtesy of E.Lakatta, NIH, USA

Page 21: NILSSON

Local Aortic Wall Angiotensin Signaling Components Increase with Aging in Humans

AC

EA

ngII

L

M

L

M

L

M

L

M

L

M

L

M

AT1

Courtesy of E.Lakatta, NIH, USA

Ang II

AT1 r

ACE

Young Old

Page 22: NILSSON

AT-1 and ACE in the Human Aortic Media Increase with Aging

Young Old

Courtesy of E.Lakatta, NIH, USA

Page 23: NILSSON

Future directions (2)

• Translational research

– Genetics, telomere biology– Mechanisms– New drug targets

Page 24: NILSSON

Telomere length has been associated with cardiovascular risk – but not in a constant way

• Smoking• Obesity• Arterial stiffness• Oxidative stress• Diabetes mellitus, type 1 and type 2

• Atherosclerotic plaques• Aortic aneurysm• Intima media thickness• Left ventricular mass (LVM)• Coronary artery disease

Nordfjäll K, et al. 2008

Page 25: NILSSON

Shorter telomeres in plaques in Shorter telomeres in plaques in art. art. carotiscarotis

Hypertension 2004;43:182

Page 26: NILSSON

Association between IMTcc (cm) and quartiles of LTL after adjusting for age, sex, smoking in pack-years, diabetes, hypertension, T-Chol and BMI in men and women

Leukocyte telomere length is associated with measuresof subclinical atherosclerosis

Panayiotou AG, et al. Atherosclerosis. 2010 Feb 4 - online

Page 27: NILSSON

”Our data show that patients with AAA have shorter leukocyte telomerelength compared to controls. This suggests that vascular biological agingmay have a role in the pathogenesis of AAA”.

Abdominal Aortic Aneurysm (AAA)

Atturu G, et al. Eur J Vasc Endovasc Surg. 2010 May;39(5):559-64.

Page 28: NILSSON

T/S means and standard deviation in 272 subjects: CTR, Type2DM and Type2DM + MI. p < 0.01 One-way analysis of variance adjusted for age and gender, F = 34.37, df = 2, p = 0.005.

Olivieri F, et al. Atherosclerosis. 2009 Oct;206:588-93

Telomere length in patients with DM2 and myocardial infarction

Page 29: NILSSON

Telomere attrition is associated with markers of cardiovascular ageing – the

Malmo Diet Cancer Study

Peter Nilsson, Disa Dahlman, Göran Roos, Olle Melander, et al.

Lund and Umeå University2010

Preliminary analyses!

Page 30: NILSSON

Malmo Diet Cancer –CV cohort

• Baseline examination in 1992-1996 (n= 6050)

• MI cases and matched controls (n= 710)

• Re-exam in 2007-2009 (n= 353)

• Telomere length determination in 750 at baseline and in 333 subjects at follow-up after mean 15 years

• Lab: q-PCR for LTL, as used at Umeå Lab, Dept. of Pathology (Göran Roos)

PN 2010

Page 31: NILSSON

Baseline 1992-1996

Follow-up in 2007-2009

15 year´s follow-up

Page 32: NILSSON

Δ z-score for telomere length changes

Page 33: NILSSON

Results

• Increased Z-score Δ changes (reflecting telomere attrition) was associated with:

– History of myocardial infarction (prevalent or incident)

– Treatment with anti-hypertensive drugs (a marker of long-standing hypertension)

– Pulse pressure at baseline (a marker of arterial stiffness)

• These entities are markers of cardiovascular ageing

PN 2010

Page 34: NILSSON

Telomeres and CVD - many unresolved questions

Page 35: NILSSON

Organisation Committee: Peter M Nilsson, Annika Dejmek, Göran Roos, et al

Page 36: NILSSON

Future directions (3)

• Prevention

– Lifestyle– Drug treatment– Control of ageing?

Page 37: NILSSON

Summary

• Early vascular ageing (EVA) is a useful concept for new understanding of vascular disease progression and increased CV risk

• Definitions of EVA are still preliminary and should be further evaluated, as well as the association with changes in telomere biology

• New drugs are under development for vascular protection, besides traditional BP lowering drugs

PN 2010